Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 15;13(12):4473.
doi: 10.3390/nu13124473.

The Association between Treatment Modality, Lipid Profile, Metabolic Control in Children with Type 1 Diabetes and Celiac Disease-Data from the International Sweet Registry

Monica Marino  1 , Alexander J Eckert  2 , Shoshana Tell  3 , Nevena Krnic  4 , Grazyna Deja  5 , Vinni Faber Rasmussen  6   7 , Raquel Coelho  8 , Sladjana Todorovic  9 , Craig A Jefferies  10 , Eman Sherif  11 , Carolina Martinez Mateu  12 , Maria Elena Lionetti  1
Affiliations

The Association between Treatment Modality, Lipid Profile, Metabolic Control in Children with Type 1 Diabetes and Celiac Disease-Data from the International Sweet Registry

Monica Marino et al. Nutrients. .

Abstract

Background and aims: A higher frequency of dyslipidemia is reported in children with type 1 diabetes (T1D) and celiac disease (CD). Recently, continuous subcutaneous insulin infusion (CSII) has been associated with better lipid profiles in patients with T1D. The aim of this study was to investigate the association between treatment modality and lipid profile, metabolic control, and body mass index (BMI)-SDS in children with both T1D and CD.

Methods: Cross-sectional study in children registered in the international SWEET database in November 2020. Inclusion criteria were children (2-18 years) with T1D and CD with available data on treatment modality (CSII and injections therapy, IT), triglyceride, total cholesterol, HDL, LDL, dyslipidemia, HbA1c, and BMI-SDS. Overweight/obesity was defined as > +1 BMI-SDS for age. Data were analyzed by linear and logistical regression models with adjustment for age, gender, and diabetes duration.

Results: In total 1009 children with T1D and CD (female 54%, CSII 54%, age 13.9 years ±3.6, diabetes duration 7.2 years ±4.1, HbA1c 7.9% ±1.4) were included. Significant differences between children treated with CSII vs. IT were respectively found; HDL 60.0 mg/dL vs. 57.8 mg/dL, LDL 89.4 mg/dL vs. 94.2 mg/dL, HbA1c 7.7 vs. 8.1%, BMI-SDS 0.4 vs. 0.6, overweight and obesity 17% vs. 26% (all p < 0.05).

Conclusions: CSII is associated with higher HDL and lower LDL, HbA1c, BMI-SDS, and percentage of overweight and obesity compared with IT in this study. Further prospective studies are required to determine whether CSII improves lipid profile, metabolic control and normalize body weight in children with both T1D and CD.

Keywords: celiac disease; continuous subcutaneous insulin infusion; glycemic control; lipid profile; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study flowchart, inclusion of SWEET patients. Blue = inclusion, grey = exclusion, red = final study cohort.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lionetti E., Catassi C. New Clues in Celiac Disease Epidemiology, Pathogenesis, Clinical Manifestations, and Treatment. Int. Rev. Immunol. 2011;30:219–231. doi: 10.3109/08830185.2011.602443. - DOI - PubMed
    1. Rubio-Tapia A., Ludvigsson J.F., Brantner T.L., Murray J.A., Everhart J.E. The Prevalence of Celiac Disease in the United States. Am. J. Gastroenterol. 2012;107:1538–1544. doi: 10.1038/ajg.2012.219. - DOI - PubMed
    1. Mahmud F.H., De Melo E.N., Noordin K., Assor E., Sahota K., Davies-Shaw J., Cutz E., Somers G., Lawson M., Mack D.R., et al. The Celiac Disease and Diabetes-Dietary Intervention and Evaluation Trial (CD-DIET) protocol: A randomised controlled study to evaluate treatment of asymptomatic coeliac disease in type 1 diabetes. BMJ Open. 2015;5:e008097. doi: 10.1136/bmjopen-2015-008097. - DOI - PMC - PubMed
    1. Mahmud F.H., Murray J.A., Kudva Y.C., Zinsmeister A.R., Dierkhising R.A., Lahr B.D., Dyck P.J., Kyle R.A., El-Youssef M., Burgart L.J., et al. Celiac Disease in Type 1 Diabetes Mellitus in a North American Community: Prevalence, Serologic Screening, and Clinical Features. Mayo Clin. Proc. 2005;80:1429–1434. doi: 10.4065/80.11.1429. - DOI - PMC - PubMed
    1. Lind M., Svensson A.M., Kosiborod M., Gudbjörnsdottir S., Pivodic A., Wedel H., Dahlqvist S., Clements M., Rosengren A. Glycemic Control and Excess Mortality in Type 1 Diabetes. N. Engl. J. Med. 2015;372:1972–1982. doi: 10.1056/NEJMoa1408214. - DOI - PubMed